CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
Peppermint oil +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05561543
NCT05561543N/ACompleted

Effects of Peppermint Oil in Cardiometabolic Outcomes in Participants With Mild-moderate Hypertension.

University of Central Lancashire·interventional·Posted Sep 30, 2022·Updated Jan 15, 2026

In Brief

A clinical study evaluating Peppermint oil and Placebo for Hypertension. Completed, enrolled 40 participants across 1 site.

Detailed Summary

Cardiovascular and associated hypertensive diseases are the leading health burden and cause of mortality worldwide; therefore, the necessity for effective interventions is paramount. Dietary interventions to improve cardiovascular health are highly sought after as they possess less risk and financial burden than pharmacological drugs. Our previous randomized trial has shown that oral peppermint can improving systolic blood pressure and other cardiovascular/ blood lipids in healthy individuals. However, to date, no research has explored this using a placebo randomized intervention in patients with hypertension. Therefore, the primary purpose of the proposed investigation is to test the ability of oral peppermint oil supplementation to improve cardiometabolic parameters in participants with mild-moderate hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited Kingdom

Timeline

N/ACompletedFinished
2023202420252026
First PostedSep 30, 2022
Enrollment StartJan 1, 2024
Primary CompletionAug 1, 2025
Study CompletionAug 10, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.8 years ago

Interventions

Peppermint oildietary

Peppermint oil

Placeboother

Placebo